Related Experiment Video
Updated: May 4, 2026
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation
Mustafa Zelal Muallem1, Simone Marnitz, Rolf Richter
1Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany. Mustafa-Zelal.Muallem@charite.de.
Aim:
The purpose of the present study was to evaluate the correlation between repair cross-complementing group-1 (ERCC1) status and the outcome of platin-based chemoradiation of locally advanced cervical cancer.
Patients And Methods:
Tumor specimens from 112 patients with locally advanced cervical cancer were evaluated for ERCC1 expression. The outcome of these patients was retrospectively assessed in correlation with ERCC1 expression.
Results:
Increased expression of ERCC1 correlates with a better prognosis of cervical cancer. The 2-year overall survival was 68.6% in the group with low H-score for ERCC-1 and gradually increased in the intermediate and high H-score groups to 71.7% and 90.7%, respectively.
Conclusion:
The present study did not confirm the correlation of low levels of ERCC1 expression with unfavorable outcomes of patients with locally advanced cervical cancer treated with platin-based radiochemotherapy.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025